LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
| Revenue (TTM) | $57.70M |
| Gross Profit (TTM) | $26.38M |
| EBITDA | $-11.84M |
| Operating Margin | 49.20% |
| Return on Equity | 36.20% |
| Return on Assets | -14.70% |
| Revenue/Share (TTM) | $4.79 |
| Book Value | $0.89 |
| Price-to-Book | 6.83 |
| Price-to-Sales (TTM) | 1.28 |
| EV/Revenue | 1.088 |
| EV/EBITDA | -1.04 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -5.20% |
| Shares Outstanding | $12.10M |
| Float | $8.74M |
| % Insiders | 21.50% |
| % Institutions | 52.77% |
Volatility is currently contracting